Skip to content

Latigo Biotherapeutics, Inc.

LTGO· NasdaqCore metricsCIK 2056611

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -4.52%
Market cap
$855.26M
66.3M shares
Filings
46
—
—
—
-$20.95M
Q3 2026
—
-$22.93M
Q3 2026
—
-$68.02M
Q3 2026derived
—
-$0.55
Q3 2026
—
$401.24M
Q3 2026+287.5% FY25 yoy
$855.26M
—
—
2.2×
—
—

FY2026 figures · derived

Price

$12.9029.32%$5.35since Aug 7, 2026
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Research And Development

$17.50MQ3 2026
No annual history for this metric yet.
PeriodEndedValueKindSource trail

Pharmaceutical preparations

Latigo Biotherapeutics, Inc. is the 153rd largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Latigo Biotherapeutics, Inc. · CIK 2056611 · Engraved from SEC EDGAR